Canada markets open in 6 hours 5 minutes

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
84.92+0.25 (+0.30%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close84.67
Open84.55
Bid0.00 x 1000
Ask0.00 x 800
Day's Range84.37 - 84.92
52 Week Range77.04 - 98.52
Volume1,500,696
Avg. Volume1,930,142
Market Cap189.944B
Beta (5Y Monthly)0.55
PE Ratio (TTM)21.52
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.20 (3.77%)
Ex-Dividend DateMar. 04, 2021
1y Target EstN/A
All
News
  • GlobeNewswire

    Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer

    Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)1Potentially clinically meaningful improvements in both PFS and OS were observed among pre-specified subgroups of patients with inflammatory biomarkers; additional analyses are ongoing1Results support continued study of canakinumab i

  • GlobeNewswire

    Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer

    Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care Facilitated by Novartis, Invisible Nation will aim to reduce and ultimately prevent many of the 15 million1 ASCVD deaths each year and dramatically lower what is estimated to become $1 trillion in annual CV disease care cost by 20302Network members will engage policymakers, healthcare syste

  • GlobeNewswire

    Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics

    Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporinsAcquisition confirms Sandoz commitment to antibiotics, following announcement of further investment plans for European-based manufacturing network Basel, October 11, 2021 – Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotic